中國旺旺(00151.HK)中期純利升7.1%至20.90億元 中期息0.83美仙
格隆匯11月30日丨中國旺旺(00151.HK)公佈截至2021年9月30日止6個月中期業績,期內集團實現收益113.83億元人民幣(單位下同),同比增長10.5%,創下上市以來上半年度收益新高。核心產品“旺仔牛奶”收益成長23.9%,其中財年一、二季同比成長均超過20%。
2021財年上半年,集團實現毛利53.23億元,同比增長7.2%,毛利率由上年同期的48.2%降至46.8%;營運利潤27.81億元,同比增長9.7%;公司權益持有人應占利潤20.90億元,同比增長7.1%;每股基本盈利17.32分,宣派中期股息每股0.83美仙。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.